Insulet Corporation

Day range

$142.47 – $148.35

Open

$142.47

Prev close

$148.12

Volume

1.21M

Market cap

$10.27B

Shares out

69.35M

P/E

27.37

P/S

3.36

P/B

7.22

P/FCF

36.36

ROE

26.4%

ROA

11.9%

Debt/Equity

0.67

Div yield

0.00%

As of Oct 22, 2026

• Debt activitySep 21, 2026

  On September 21, 2026, Insulet Corporation (the "Company") entered into the Ninth Amendment to Credit Agreement (the "Amendment") with the lenders and other parties thereto and Morgan Stanley Senior Funding, Inc., as administrative agent (the "Agent"), amending that certain Credit Agreement, dated as of May 4, 2021 (as previously amended, supplemented or modified, the "Credit Agreement", and as amended by the Amendment, the "Amended Credit Agreement"), by and among the Company, the lenders and other parties thereto and the Agent. In addition, pursuant to the Amendment, revolving credit commitments under the Credit Agreement were increased by $250 million and the interest rate margin applicable to revolving loans outstanding under the Amended Credit Agreement was reduced.

• Executive leadershipSep 16, 2026

  On September 14, 2026, the Talent and Compensation Committee (the "Committee") of the Board of Directors (the "Board") of Insulet Corporation (the "Company") approved and adopted the Insulet Nonqualified Deferred Compensation Plan (the "Plan"), with such Plan to be effective on January 1, 2027. The Plan is intended to be an unfunded "top hat" deferred compensation plan ... including the Company's named executive officers, to voluntarily defer compensation.

• Board of directorsSep 10, 2026

  On September 8, 2026, Michael R. Minogue also notified the Company of his decision to step down from the Board to focus on his candidacy for Governor of Massachusetts, effective September 15, 2026. Neither Mr. Scannell nor Mr. Minogue resigned due to any disagreement with the Company on any matter relating to the Company's operations, policies or practices.

• Executive leadershipJun 25, 2026

  As a non-employee director of the Company, Mr. Mazelsky will receive an initial grant of restricted stock units with a grant date fair value of $216,548, which represents a pro-rated $260,000 annual award. He will also receive cash compensation pursuant to the Company's non-employee director compensation program.

• Governance documentsMay 21, 2026

  On May 20, 2026, the Board of Directors of Insulet Corporation (the "Company") approved the amendment and restatement of the Company's Bylaws (the "Amended Bylaws"), effective immediately, to designate the Court of Chancery of the State of Delaware (or if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if such state court lacks subject matter jurisdiction, the federal district court within the State of Delaware) as the sole and exclusive forum for certain actions including derivative actions or proceedings brought on behalf of the Company and actions for breach of fiduciary duty owed by any of the Company's officers or directors.

Days to cover

3.9

Short interest

5.36M

Avg volume

1.37M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Global Digital Health and Remote Patient Monitoring Strategic Market Report, 2026-2031 | 20.2% CAGR to $80.8 Billion as Connected Care and Wearables Scale
  positiveGlobeNewswire Inc.· Oct 21, 2026
• DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study
  positiveZacks Investment Research· Oct 20, 2026
• Here's Why Insulet (PODD) is a Strong Growth Stock
  positiveZacks Investment Research· Oct 16, 2026
• Is it Prudent to Retain Insulet Stock in Your Portfolio for Now?
  neutralZacks Investment Research· Sep 8, 2026
• ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Blaize Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - BZAI
  negativeGlobeNewswire Inc.· Aug 29, 2026